Centiva Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-30,700
Closed -$2.57M 1941
2024
Q3
$2.57M Buy
30,700
+15,000
+96% +$1.14M 0.05% 344
2024
Q2
$1.08M Buy
15,700
+10,000
+175% +$667K 0.02% 734
2024
Q1
$418K Sell
5,700
-4,300
-43% -$331K 0.01% 1080
2023
Q4
$810K Sell
10,000
-22,100
-69% -$1.72M 0.02% 712
2023
Q3
$2.41M Buy
32,100
+22,100
+221% +$1.7M 0.05% 335
2023
Q2
$771K Sell
10,000
-10,000
-50% -$798K 0.02% 660
2023
Q1
$1.66M Hold
20,000
0.04% 460
2022
Q4
$1.72M Sell
20,000
-30,000
-60% -$2.38M 0.05% 402
2022
Q3
$3.08M Sell
50,000
-11,800
-19% -$744K 0.06% 246
2022
Q2
$3.82M Sell
61,800
-55,100
-47% -$3.41M 0.09% 194
2022
Q1
$6.95M Sell
116,900
-74,000
-39% -$4.73M 0.13% 105
2021
Q4
$13.9M Buy
190,900
+190,230
+28,393% +$13.1M 0.29% 60
2021
Q3
$47K Sell
670
-19,330
-97% -$1.36M ﹤0.01% 1132
2021
Q2
$1.38M Buy
+20,000
New +$1.34M 0.03% 442
2021
Q1
Sell
-5,200
Closed -$302K 1241
2020
Q4
$302K Sell
5,200
-37,000
-88% -$2.23M 0.01% 650
2020
Q3
$2.67M Buy
42,200
+9,500
+29% +$659K 0.18% 97
2020
Q2
$2.52M Sell
32,700
-43,200
-57% -$3.31M 0.15% 85
2020
Q1
$5.67M Buy
75,900
+7,700
+11% +$532K 0.25% 54
2019
Q4
$4.43M Buy
68,200
+52,900
+346% +$3.44M 0.22% 96
2019
Q3
$970K Buy
15,300
+14,700
+2,450% +$961K 0.06% 220
2019
Q2
$41K Sell
600
-79,600
-99% -$5.24M ﹤0.01% 400
2019
Q1
$5.21M Buy
80,200
+44,000
+122% +$2.92M 0.35% 44
2018
Q4
$2.27M Buy
36,200
+2,300
+7% +$161K 0.18% 81
2018
Q3
$2.62M Buy
33,900
+17,900
+112% +$1.35M 0.23% 68
2018
Q2
$1.13M Sell
16,000
-1,000
-6% -$70.6K 0.24% 35
2018
Q1
$1.28M Hold
17,000
0.31% 22
2017
Q4
$1.22M Buy
+17,000
New +$1.29M 0.1% 9

Other funds holding GILD

Centiva Capital's GILD Position: Q1 2026 in Review

Centiva Capital reduced its Gilead Sciences (GILD) stake by 6.2% in Q1 2026, selling an estimated $15.3K and leaving 1,652 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Centiva Capital first reported a position in GILD in Q1 2018 and has held it in 26 quarters since. The position peaked at $6.01M in Q1 2023. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Centiva Capital held 1,652 shares of Gilead Sciences worth $230K as of Q1 2026.
  • Centiva Capital sold 109 Gilead Sciences shares in Q1 2026, an estimated $15.3K.
  • Gilead Sciences made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1204 holding.
  • Centiva Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 26 quarters since.
  • Centiva Capital's Gilead Sciences position peaked at $6.01M in Q1 2023.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.